Media Centre

Featured Media Release
 

10 Sep 2013 - GlaxoSmithKline reaches agreement to divest Lucozade and Ribena for £1.35 billion

GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd (SBF), the Japanese consumer goods company, for £1.35 billion in cash. It is expected that the transaction will be completed by the end of the year, subject to regulatory approvals.

 
 

Media Releases


Medicines Research Unit to Close

GSK today announced it will be closing the Medicines Research Unit at the Prince of Wales Hospital in Sydney.

28/08/2014

 

GSK Open Innovation brings opportunities to Australian & NZ innovators

An innovation program that helps develop ground-breaking health sector ideas around the world is calling upon Australian and New Zeland innovators to submit their ideas to the GSK Open Innovation website.

07/08/2014

 

GSK Response to Publication of Paracetamol in Low Back Pain Study (PACE)

Panadol is approved by the TGA for the effective relief of backache.

24/07/2014

 

New medicine for lupus now available in Australia

GSK is pleased to announce that BENLYSTA® (belimumab) is now available in Australia for use as an add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite...

23/07/2014

 

Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease...

15/07/2014

 

Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in...

09/07/2014

 

GSK RECOGNISES TOP POPPY GROWERS

Leaders in Australian poppy production, GSK awarded its top poppy producers at an award dinner

30/06/2014

 

$80,000 to local communities to boost immunisation

GSK’s 2014 Immunisation Grants for local communities were launched today at the Public Health Association of Australia’s 14th annual immunisation conference. The grants aim to help improve access, coverage and timely delivery of vaccination services.

17/06/2014

 

GSK Response to CHOICE Media Release

GSK would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.

12/06/2014

 

GSK Australia Reports 2013 results to ASIC

GSK Australia reported to the Australian Securities and Investment Commission (ASIC) for 2013, sales of $1,414m and a total profit before tax of $42m.

03/06/2014

1 2 3 4 5 6 7 8 9 10 11 >